{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:53Z","timestamp":1792782533044,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EU-Horizon 2020 Marie Sk\u0142odowska-Curie actions (MSCA) ITN project BIORAPID","award":["643056"],"award-info":[{"award-number":["643056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00204-016-1876-7","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T04:25:21Z","timestamp":1476937521000},"page":"1595-1612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6939-6416","authenticated-orcid":false,"given":"Arathi","family":"Kizhedath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarka","family":"Glassey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"key":"1876_CR1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10659360600787551","volume":"17","author":"T Abshear","year":"2006","unstructured":"Abshear T, Banik GM, D\u2019Souza ML, Nedwed K, Peng C (2006) A model validation and consensus building environment. SAR QSAR Environ Res 17:311\u2013321","journal-title":"SAR QSAR Environ Res"},{"key":"1876_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/1062936X.2015.1018941","volume":"26","author":"P Ashrafi","year":"2015","unstructured":"Ashrafi P, Moss GP, Wilkinson SC, Davey N, Sun Y (2015) The application of machine learning to the modelling of percutaneous absorption: an overview and guide. SAR QSAR Environ Res 26:181\u2013204","journal-title":"SAR QSAR Environ Res"},{"key":"1876_CR3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang H-W, Shekhar K, Gupta S (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:224\u2013228","journal-title":"Nature"},{"key":"1876_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10295-013-1235-0","volume":"40","author":"A Berlec","year":"2013","unstructured":"Berlec A, \u0160trukelj B (2013) Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells. J Ind Microbiol Biotechnol 40:257\u2013274","journal-title":"J Ind Microbiol Biotechnol"},{"key":"1876_CR5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1517\/14712590903110709","volume":"9","author":"WK Boland","year":"2009","unstructured":"Boland WK, Bebb G (2009) Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Exp Opin Biol Ther 9:1199\u20131206","journal-title":"Exp Opin Biol Ther"},{"key":"1876_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/eji.1830230216","volume":"23","author":"S Bolt","year":"1993","unstructured":"Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23:403\u2013411","journal-title":"Eur J Immunol"},{"key":"1876_CR7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","volume":"158","author":"S Bournazos","year":"2014","unstructured":"Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:1243\u20131253","journal-title":"Cell"},{"key":"1876_CR8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/0161-5890(95)00118-2","volume":"32","author":"PN Boyd","year":"1995","unstructured":"Boyd PN, Lines AC, Patel AK (1995) The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32:1311\u20131318","journal-title":"Mol Immunol"},{"key":"1876_CR9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","volume":"6","author":"PJ Carter","year":"2006","unstructured":"Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343\u2013357","journal-title":"Nat Rev Immunol"},{"key":"1876_CR10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrd822","volume":"1","author":"JA Cavagnaro","year":"2002","unstructured":"Cavagnaro JA (2002) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 1:469\u2013475","journal-title":"Nat Rev Drug Discov"},{"key":"1876_CR11","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/ci900115y","volume":"49","author":"V Consonni","year":"2009","unstructured":"Consonni V, Ballabio D, Todeschini R (2009) Comments on the definition of the Q 2 parameter for QSAR validation. J Chem Inf Model 49:1669\u20131678","journal-title":"J Chem Inf Model"},{"key":"1876_CR12","doi-asserted-by":"crossref","DOI":"10.1039\/9781849732093","volume-title":"In silico toxicology: principles and applications","author":"MTD Cronin","year":"2010","unstructured":"Cronin MTD, Madden JC (2010) In silico toxicology: principles and applications. Royal Society of Chemistry, London"},{"key":"1876_CR13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C","volume":"36","author":"SD Demo","year":"1999","unstructured":"Demo SD, Masuda E, Rossi AB, Throndset BT, Gerard AL, Chan EH, Armstrong RJ, Fox BP, Lorens JB, Payan DG (1999) Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay. Cytometry 36:340\u2013348","journal-title":"Cytometry"},{"key":"1876_CR14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/protein\/gzt020","volume":"26","author":"J Dunbar","year":"2013","unstructured":"Dunbar J, Fuchs A, Shi J, Deane CM (2013) ABangle: characterising the VH\u2013VL orientation in antibodies. Prot Eng Des Sel 26:611\u2013620","journal-title":"Prot Eng Des Sel"},{"issue":"1","key":"1876_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","volume":"7","author":"DM Ecker","year":"2015","unstructured":"Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody marketed. MAbs 7(1):9\u201314","journal-title":"MAbs"},{"key":"1876_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.vascn.2013.12.003","volume":"69","author":"S Ekins","year":"2014","unstructured":"Ekins S (2014) Progress in computational toxicology. J Pharmacol Toxicol Methods 69:115\u2013140","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1876_CR17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/10_2012_171","volume-title":"Measurement, monitoring, modelling and control of bioprocesses","author":"J Glassey","year":"2012","unstructured":"Glassey J (2012) Multivariate data analysis for advancing the interpretation of bioprocess measurement and monitoring data. In: Measurement, monitoring, modelling and control of bioprocesses. Springer, Heidelberg, pp 167\u2013191"},{"key":"1876_CR18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","volume":"526","author":"J Golay","year":"2012","unstructured":"Golay J, Introna M (2012) Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 526:146\u2013153","journal-title":"Arch Biochem Biophys"},{"key":"1876_CR19","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383\u20133389","journal-title":"Blood"},{"key":"1876_CR20","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1182\/blood-2010-06-289736","volume":"116","author":"J Golay","year":"2010","unstructured":"Golay J, Bologna L, Andr\u00e9 P-A, Buchegger F, Mach JP, Boumsell L, Introna M (2010) Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 116:3372\u20133373","journal-title":"Blood"},{"key":"1876_CR21","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","volume":"122","author":"J Golay","year":"2013","unstructured":"Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M (2013) Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122:3482\u20133491","journal-title":"Blood"},{"key":"1876_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jctb.4481","volume":"90","author":"A Green","year":"2015","unstructured":"Green A, Glassey J (2015) Multivariate analysis of the effect of operating conditions on hybridoma cell metabolism and glycosylation of produced antibody. J Chem Technol Biotechnol 90:303\u2013313","journal-title":"J Chem Technol Biotechnol"},{"key":"1876_CR23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1039\/C5TX00055F","volume":"4","author":"N Greene","year":"2015","unstructured":"Greene N, Pennie W (2015) Computational toxicology, friend or foe? Toxicol Res 4:1159\u20131172","journal-title":"Toxicol Res"},{"key":"1876_CR24","unstructured":"Guideline ICHHT (1997) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use"},{"key":"1876_CR25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0378-4274(95)03356-P","volume":"79","author":"C Hansch","year":"1995","unstructured":"Hansch C, Hoekman D, Leo A, Zhang L, Li P (1995) The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett 79:45\u201353","journal-title":"Toxicol Lett"},{"key":"1876_CR26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325\u2013338","journal-title":"Nat Rev Drug Discov"},{"key":"1876_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-2946-2-7","volume":"2","author":"B Hardy","year":"2010","unstructured":"Hardy B, Douglas N, Helma C, Rautenberg M, Jeliazkova N, Jeliazkov V, Nikolova I, Benigni R, Tcheremenskaia O, Kramer S (2010) Collaborative development of predictive toxicology applications. J Cheminform 2:1\u201329","journal-title":"J Cheminform"},{"key":"1876_CR28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40\u201351","journal-title":"Nat Biotechnol"},{"key":"1876_CR29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/ci700016d","volume":"47","author":"M Hewitt","year":"2007","unstructured":"Hewitt M, Cronin MTD, Madden JC, Rowe PH, Johnson C, Obi A, Enoch SJ (2007) Consensus QSAR models: do the benefits outweigh the complexity? J Chem Inf Model 47:1460\u20131468","journal-title":"J Chem Inf Model"},{"key":"1876_CR30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/nbt1337","volume":"25","author":"A Jakobovits","year":"2007","unstructured":"Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134\u20131143","journal-title":"Nat Biotechnol"},{"key":"1876_CR31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrd2804","volume":"8","author":"R Jefferis","year":"2009","unstructured":"Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226\u2013234","journal-title":"Nat Rev Drug Discov"},{"key":"1876_CR32","doi-asserted-by":"crossref","unstructured":"Jefferis R (2014) Monoclonal antibodies: mechanisms of action. In: State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization volume 1 monoclonal antibody therapeutics: structure, function, and regulatory space, vol 1176. American Chemical Society, pp 35\u201368","DOI":"10.1021\/bk-2014-1176.ch002"},{"key":"1876_CR33","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/321522a0","volume":"321","author":"PT Jones","year":"1985","unstructured":"Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1985) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522\u2013525","journal-title":"Nature"},{"key":"1876_CR34","volume-title":"Kuby immunology","author":"TJ Kindt","year":"2007","unstructured":"Kindt TJ, Goldsby RA, Osborne BA, Kuby J (2007) Kuby immunology. Macmillan, London"},{"key":"1876_CR35","doi-asserted-by":"crossref","first-page":"W349","DOI":"10.1093\/nar\/gkv535","volume":"43","author":"MS Klausen","year":"2015","unstructured":"Klausen MS, Anderson MV, Jespersen MC, Nielsen M, Marcatili P (2015) LYRA, a webserver for lymphocyte receptor structural modeling. Nucleic Acids Res 43:W349\u2013W355","journal-title":"Nucleic Acids Res"},{"key":"1876_CR36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"1876_CR37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711\u2013716","journal-title":"Nat Rev Drug Discov"},{"key":"1876_CR38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/ph6050579","volume":"6","author":"T Lai","year":"2013","unstructured":"Lai T, Yang Y, Ng SK (2013) Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals 6:579\u2013603","journal-title":"Pharmaceuticals"},{"key":"1876_CR39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jim.2005.12.007","volume":"309","author":"GE Lash","year":"2006","unstructured":"Lash GE, Scaife PJ, Innes BA, Otun HA, Robson SC, Searle RF, Bulmer JN (2006) Comparison of three multiplex cytokine analysis systems: luminex, SearchLight\u2122 and FAST Quant\u00ae. J Immunol Methods 309:205\u2013208","journal-title":"J Immunol Methods"},{"key":"1876_CR40","doi-asserted-by":"crossref","first-page":"L1006","DOI":"10.1093\/nar\/gkn838","volume":"37","author":"M-P Lefranc","year":"2009","unstructured":"Lefranc M-P, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, Wu Y, Gemrot E, Brochet X, Lane JM (2009) IMGT\u00ae, the international ImMunoGeneTics information system\u00ae. Nucleic Acids Res 37:L1006\u2013L1012","journal-title":"Nucleic Acids Res"},{"key":"1876_CR41","doi-asserted-by":"crossref","first-page":"D413","DOI":"10.1093\/nar\/gku1056","volume":"43","author":"M-P Lefranc","year":"2015","unstructured":"Lefranc M-P, Giudicelli V, Duroux P, Jabado-Michaloud J, Folch G, Aouinti S, Carillon E, Duvergey H, Houles A, Paysan-Lafosse T (2015) IMGT\u00ae, the international ImMunoGeneTics information system\u00ae 25\u00a0years on. Nucleic Acids Res 43:D413\u2013D422","journal-title":"Nucleic Acids Res"},{"key":"1876_CR42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/aps.2010.120","volume":"31","author":"J Li","year":"2010","unstructured":"Li J, Zhu Z (2010) Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 31:1198\u20131207","journal-title":"Acta Pharmacol Sin"},{"key":"1876_CR43","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","volume":"104","author":"L Liu","year":"2015","unstructured":"Liu L (2015) Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104:1866\u20131884","journal-title":"J Pharm Sci"},{"key":"1876_CR44","unstructured":"Lower PATA (2015) Mechanism of action. Drugs"},{"key":"1876_CR45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/jpet.112.191999","volume":"341","author":"KT Luu","year":"2012","unstructured":"Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E (2012) A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 341:702\u2013708","journal-title":"J Pharmacol Exp Ther"},{"key":"1876_CR46","first-page":"794","volume":"4","author":"JKC Ma","year":"2003","unstructured":"Ma JKC, Drake PMW, Christou P (2003) The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 4:794\u2013805","journal-title":"Nat Rev Genet"},{"key":"1876_CR47","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1038\/nprot.2014.189","volume":"9","author":"P Marcatili","year":"2014","unstructured":"Marcatili P, Olimpieri PP, Chailyan A, Tramontano A (2014) Antibody modeling using the Prediction of ImmunoGlobulin Structure (PIGS) web server. Nat Protoc 9:2771\u20132783","journal-title":"Nat Protoc"},{"key":"1876_CR48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.toxlet.2014.06.008","volume":"229","author":"CA Moore","year":"2014","unstructured":"Moore CA, Wilkinson SC, Blain PG, Dunn M, Aust GA, Williams FM (2014) Percutaneous absorption and distribution of organophosphates (chlorpyrifos and dichlorvos) following dermal exposure and decontamination scenarios using in vitro human skin model. Toxicol Lett 229:66\u201372","journal-title":"Toxicol Lett"},{"key":"1876_CR49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1017\/CBO9780511596773.011","volume-title":"Recombinant antibodies for immunotherapy","author":"A Murphy","year":"2009","unstructured":"Murphy A (2009) VelocImmune: immunoglobulin variable region humanized mice. Recombinant antibodies for immunotherapy. Cambridge university, GB, pp 100\u2013107"},{"key":"1876_CR50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12245","volume":"263","author":"MH Nelson","year":"2015","unstructured":"Nelson MH, Paulos CM (2015) Novel immunotherapies for hematologic malignancies. Immunol Rev 263:90\u2013105","journal-title":"Immunol Rev"},{"key":"1876_CR51","doi-asserted-by":"crossref","unstructured":"Olimpieri PP, Chailyan A, Tramontano A, Marcatili P (2013).Prediction of site-specific interactions in antibody-antigen complexes: the proABC method and server. Bioinformatics btt369","DOI":"10.1093\/bioinformatics\/btt369"},{"key":"1876_CR52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10067-013-2252-0","volume":"32","author":"R Peluso","year":"2013","unstructured":"Peluso R, Cafaro G, Di Minno A, Iervolino S, Ambrosino P, Lupoli G, Di Minno MND (2013) Side effects of TNF-\u03b1 blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol 32:743\u2013753","journal-title":"Clin Rheumatol"},{"key":"1876_CR53","unstructured":"Pharma E (2014) World preview 2014, outlook to 2020"},{"key":"1876_CR54","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00439-001-0615-0","volume":"109","author":"S Povey","year":"2001","unstructured":"Povey S, Lovering R, Bruford E, Wright M, Lush M, Wain H (2001) The HUGO gene nomenclature committee (HGNC). Hum Genet 109:678\u2013680","journal-title":"Hum Genet"},{"key":"1876_CR55","doi-asserted-by":"crossref","first-page":"e0122416","DOI":"10.1371\/journal.pone.0122416","volume":"10","author":"T Qiu","year":"2015","unstructured":"Qiu T, Xiao H, Zhang Q, Qiu J, Yang Y, Wu D, Cao Z, Zhu R (2015) Proteochemometric modeling of the antigen-antibody interaction: new fingerprints for antigen, antibody and epitope\u2013paratope interaction. PLoS One 10:e0122416","journal-title":"PLoS One"},{"key":"1876_CR56","unstructured":"Qiu T, Qiu J, Feng J, Wu D, Yang Y, Tang K, Cao Z, Zhu R (2016) The recent progress in proteochemometric modelling: focusing on target descriptors, cross-term descriptors and application scope. In: Briefings in bioinformatics, bbw004"},{"issue":"3","key":"1876_CR57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4161\/mabs.19868","volume":"4","author":"TS Raju","year":"2012","unstructured":"Raju TS, Jordan RE (2012) Galactosylation variations in marketed therapeutic antibodies. MAbs 4(3):385\u2013391","journal-title":"MAbs"},{"key":"1876_CR58","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715\u2013725","journal-title":"Nat Rev Immunol"},{"key":"1876_CR59","doi-asserted-by":"crossref","first-page":"e58724","DOI":"10.1371\/journal.pone.0058724","volume":"8","author":"Y Rosenberg","year":"2013","unstructured":"Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S, Urban L, Landucci G, Fischer R, Jiang X (2013) Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One 8:e58724","journal-title":"PLoS One"},{"key":"1876_CR60","first-page":"1","volume":"16","author":"YB Ruiz-Blanco","year":"2015","unstructured":"Ruiz-Blanco YB, Paz W, Green J, Marrero-Ponce Y (2015) ProtDCal: a program to compute general-purpose-numerical descriptors for sequences and 3D-structures of proteins. BMC Bioinform 16:1","journal-title":"BMC Bioinform"},{"key":"1876_CR61","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00204-013-1179-1","volume":"88","author":"J Shao","year":"2014","unstructured":"Shao J, Berger LF, Hendriksen PJM, Peijnenburg AACM, van Loveren H, Volger OL (2014) Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol 88:673\u2013689","journal-title":"Arch Toxicol"},{"key":"1876_CR62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nbt0410-307","volume":"28","author":"C Sheridan","year":"2010","unstructured":"Sheridan C (2010) Fresh from the biologic pipeline [mdash] 2009. Nat Biotechnol 28:307\u2013310","journal-title":"Nat Biotechnol"},{"key":"1876_CR63","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B (2001) High resolution mapping of the binding site on human IgG1 for Fc\u03b3RI, Fc\u03b3RII, Fc\u03b3RIII, and FcRn and design of IgG1 variants with improved binding to the Fc\u03b3R. J Biol Chem 276:6591\u20136604","journal-title":"J Biol Chem"},{"key":"1876_CR64","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, Lai J, Keck R, O\u2019Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG (2002) Lack of fucose on human IgG1\u00a0N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733\u201326740","journal-title":"J Biol Chem"},{"key":"1876_CR65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1248\/yakushi.129.3","volume":"129","author":"K Shitara","year":"2009","unstructured":"Shitara K (2009) [Potelligent antibodies as next generation therapeutic antibodies]. Yakugaku zasshi. J Pharm Soc Jpn 129:3\u20139","journal-title":"J Pharm Soc Jpn"},{"key":"1876_CR66","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.4049\/jimmunol.179.5.3325","volume":"179","author":"R Stebbings","year":"2007","unstructured":"Stebbings R, Findlay L, Edwards C, Eastwood D, Bird C, North D, Mistry Y, Dilger P, Liefooghe E, Cludts I (2007) \u201cCytokine storm\u201d in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179:3325\u20133331","journal-title":"J Immunol"},{"key":"1876_CR67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/1547691X.2012.711783","volume":"10","author":"R Stebbings","year":"2013","unstructured":"Stebbings R, Eastwood D, Poole S, Thorpe R (2013) After TGN1412: recent developments in cytokine release assays. J Immunotoxicol 10:75\u201382","journal-title":"J Immunotoxicol"},{"key":"1876_CR68","first-page":"175","volume":"166","author":"A Strasser","year":"2013","unstructured":"Strasser A, Harris AW, Vaux DL, Webb E, Bath ML, Adams JM, Cory S (2013) Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr Top Microbiol Immunol 166:175\u2013181 (1990b)","journal-title":"Curr Top Microbiol Immunol"},{"key":"1876_CR69","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018\u20131028","journal-title":"N Engl J Med"},{"key":"1876_CR70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/6179","volume":"17","author":"P Uma\u00f1a","year":"1999","unstructured":"Uma\u00f1a P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176\u2013180","journal-title":"Nat Biotechnol"},{"key":"1876_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-2946-5-1","volume":"5","author":"GJP Westen van","year":"2013","unstructured":"van Westen GJP, Swier RF, Wegner JK, Ijzerman AP, van Vlijmen HWT, Bender A (2013a) Benchmarking of protein descriptor sets in proteochemometric modeling (part 1): comparative study of 13 amino acid descriptor sets. J Cheminform 5:1","journal-title":"J Cheminform"},{"key":"1876_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-2946-5-1","volume":"5","author":"GJP Westen van","year":"2013","unstructured":"van Westen GJP, Swier RF, Cortes-Ciriano I, Wegner JK, Overington JP, Ijzerman AP, van Vlijmen HWT, Bender A (2013b) Benchmarking of protein descriptor sets in proteochemometric modeling (part 2): modeling performance of 13 amino acid descriptor sets. J Cheminform 5:1","journal-title":"J Cheminform"},{"key":"1876_CR73","unstructured":"Varma A, Cuenca J, Zhu Y (2014) Compostions and methods for producing glycoproteins. Google patents"},{"key":"1876_CR74","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-pharmtox-010715-103354","volume":"56","author":"J Whritenour","year":"2016","unstructured":"Whritenour J, Casinghino S, Collinge M, Zhu X (2016) Nonclinical tools to assess risk of drug hypersensitivity reactions. Annu Rev Pharmacol Toxicol 56:561\u2013576","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1876_CR75","doi-asserted-by":"crossref","DOI":"10.1039\/9781849733045","volume-title":"New Horizons in Predictive Toxicology: Current Status and Application","author":"AGE Wilson","year":"2011","unstructured":"Wilson AGE (2011) New Horizons in Predictive Toxicology: Current Status and Application. Royal Society of Chemistry, London"},{"key":"1876_CR76","first-page":"1","volume":"5","author":"World Health O","year":"2006","unstructured":"World Health O (2006) International nonproprietary names (INN) for biological and biotechnological substances. INN Working document 5:1\u201329","journal-title":"INN Working document"},{"key":"1876_CR77","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jmgm.2006.12.002","volume":"26","author":"C Zhao","year":"2007","unstructured":"Zhao C, Zhang H, Luan F, Zhang R, Liu M, Hu Z, Fan B (2007) QSAR method for prediction of protein-peptide binding affinity: application to MHC class I molecule HLA-A* 0201. J Mol Graph Model 26:246\u2013254","journal-title":"J Mol Graph Model"},{"key":"1876_CR78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/157340908786785994","volume":"4","author":"P Zhou","year":"2008","unstructured":"Zhou P, Tian F, Wu Y, Li Z, Shang Z (2008) Quantitative sequence-activity model (QSAM): applying QSAR strategy to model and predict bioactivity and function of peptides, proteins and nucleic acids. Curr Comput Aided Drug Des 4:311\u2013321","journal-title":"Curr Comput Aided Drug Des"},{"key":"1876_CR79","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.biotechadv.2011.08.022","volume":"30","author":"J Zhu","year":"2012","unstructured":"Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30:1158\u20131170","journal-title":"Biotechnol Adv"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-016-1876-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-016-1876-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-016-1876-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T16:54:12Z","timestamp":1568480052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-016-1876-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s00204-016-1876-7","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}